EA200970738A1 - Ингибиторы активности akt - Google Patents
Ингибиторы активности aktInfo
- Publication number
- EA200970738A1 EA200970738A1 EA200970738A EA200970738A EA200970738A1 EA 200970738 A1 EA200970738 A1 EA 200970738A1 EA 200970738 A EA200970738 A EA 200970738A EA 200970738 A EA200970738 A EA 200970738A EA 200970738 A1 EA200970738 A1 EA 200970738A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- akt activity
- activity inhibitors
- inhibitors
- compounds
- akt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Изобретение представляет новые гетероциклические карбоксамидные соединения, применение таких соединений в качестве ингибиторов активности протеинкиназ В и для лечения рака и артрита.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88858607P | 2007-02-07 | 2007-02-07 | |
PCT/US2008/053269 WO2008098104A1 (en) | 2007-02-07 | 2008-02-07 | Inhibitors of akt activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970738A1 true EA200970738A1 (ru) | 2010-06-30 |
EA018038B1 EA018038B1 (ru) | 2013-05-30 |
Family
ID=39682107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970738A EA018038B1 (ru) | 2007-02-07 | 2008-02-07 | ИНГИБИТОРЫ АКТИВНОСТИ Akt |
Country Status (35)
Country | Link |
---|---|
US (7) | US8410158B2 (ru) |
EP (1) | EP2117523B1 (ru) |
JP (3) | JP4723677B2 (ru) |
KR (3) | KR101521002B1 (ru) |
CN (1) | CN101646427B (ru) |
AR (1) | AR066184A1 (ru) |
AU (1) | AU2008213694B2 (ru) |
BR (1) | BRPI0807146B8 (ru) |
CA (1) | CA2678255C (ru) |
CL (1) | CL2008000348A1 (ru) |
CO (1) | CO6220930A2 (ru) |
CR (1) | CR10995A (ru) |
CY (1) | CY1115535T1 (ru) |
DK (1) | DK2117523T3 (ru) |
DO (1) | DOP2009000196A (ru) |
EA (1) | EA018038B1 (ru) |
ES (1) | ES2501518T3 (ru) |
HK (1) | HK1132676A1 (ru) |
HR (1) | HRP20140790T1 (ru) |
IL (1) | IL200212A (ru) |
JO (1) | JO3134B1 (ru) |
MA (1) | MA31167B1 (ru) |
MX (2) | MX367398B (ru) |
MY (1) | MY164480A (ru) |
NZ (1) | NZ579177A (ru) |
PE (1) | PE20090058A1 (ru) |
PL (1) | PL2117523T3 (ru) |
PT (1) | PT2117523E (ru) |
SG (1) | SG193678A1 (ru) |
SI (1) | SI2117523T1 (ru) |
TW (2) | TWI381836B (ru) |
UA (1) | UA102992C2 (ru) |
UY (1) | UY30892A1 (ru) |
WO (1) | WO2008098104A1 (ru) |
ZA (1) | ZA200905363B (ru) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
AR075153A1 (es) * | 2009-01-30 | 2011-03-16 | Glaxosmithkline Llc | Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la |
EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
IN2012DN00720A (ru) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
KR101739158B1 (ko) * | 2009-09-23 | 2017-05-23 | 노파르티스 아게 | 조합물 |
MX2012003546A (es) * | 2009-09-23 | 2012-09-07 | Glaxosmithkline Llc | Combinacion. |
US8796298B2 (en) * | 2009-10-08 | 2014-08-05 | Glaxosmithkline Llc | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer |
BR112012008271A2 (pt) * | 2009-10-08 | 2015-09-22 | Glaxosmithkline Llc | combinação |
WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
AU2011238616B2 (en) | 2010-03-30 | 2016-08-04 | Verseon Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
EP2572199B1 (en) | 2010-05-21 | 2017-03-08 | Novartis AG | Combination |
WO2011150044A1 (en) * | 2010-05-26 | 2011-12-01 | Glaxosmithkline Llc | Combination |
JP2013533318A (ja) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2012021696A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
JP2013542941A (ja) | 2010-10-13 | 2013-11-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
US20120184542A1 (en) | 2011-01-19 | 2012-07-19 | Kevin Anderson | Pyrido pyrimidines |
US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
BR112014001244A2 (pt) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | métodos para a síntese de ácidos nucléicos funcionalizados |
WO2013096630A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
MX2014012904A (es) * | 2012-04-24 | 2014-11-21 | Glaxosmithkline Ip No 2 Ltd | Carboxamidas y sus sales farmaceuticamente aceptables para usarse en el tratamiento de dermatosis sensibles a esteroides. |
EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
BR112015000784A8 (pt) | 2012-07-13 | 2018-04-03 | Wave Life Sciences Japan | Grupo auxiliar assimétrico |
EP2873674B1 (en) | 2012-07-13 | 2020-05-06 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
CA2884848C (en) | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
AR093017A1 (es) | 2012-10-16 | 2015-05-13 | Janssen Pharmaceutica Nv | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO |
BR112015008515A2 (pt) | 2012-10-16 | 2017-07-04 | Janssen Pharmaceutica Nv | moduladores de ror t de quinolinila ligada à heteroarila |
CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
US20150272952A1 (en) * | 2012-10-22 | 2015-10-01 | Glaxosmithkline Llc | Combination |
IL300664A (en) | 2012-11-30 | 2023-04-01 | Novartis Ag | Innovative pharmaceutical composition |
EP2943199A1 (en) | 2013-01-09 | 2015-11-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Combination |
US10053454B2 (en) | 2013-02-27 | 2018-08-21 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
MX2015011567A (es) * | 2013-03-15 | 2016-04-25 | Verseon Corp | Halogeno-pirazoles como inhibidores de trombina. |
EP3421036B8 (en) | 2013-03-15 | 2020-12-30 | Verseon International Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US20160235714A1 (en) * | 2013-10-01 | 2016-08-18 | Novartis Ag | Enzalutamide in combination with afuresertib for the treatment of cancer |
JP2016531884A (ja) | 2013-10-01 | 2016-10-13 | ノバルティス アーゲー | 組合せ物 |
EP3560920A1 (en) | 2013-10-15 | 2019-10-30 | Janssen Pharmaceutica NV | Secondary alcohol quinolinyl modulators of ror gamma t |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
EP3466949B1 (en) | 2013-12-24 | 2020-12-23 | Bristol-Myers Squibb Company | Tricyclic compound as anticancer agents |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
KR20230152178A (ko) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
RU2016139697A (ru) | 2014-03-12 | 2018-04-12 | Новартис Аг | Комбинация, содержащая ингибитор btk и ингибитор akt |
CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
KR102509043B1 (ko) | 2014-06-06 | 2023-03-09 | 리써치 트라이앵글 인스티튜트 | 아펠린 수용체(apj) 효능제 및 이의 용도 |
JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
KR20170122767A (ko) | 2015-02-27 | 2017-11-06 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 치환된 피라졸 화합물 |
US20180256557A1 (en) | 2015-08-28 | 2018-09-13 | Giordano Caponigro | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
JP2019501899A (ja) | 2015-12-09 | 2019-01-24 | リサーチ トライアングル インスティテュート | 改良アペリンレセプター(apj)アゴニストおよびその使用 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
JP6900406B2 (ja) * | 2016-06-16 | 2021-07-07 | ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド | Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物 |
KR102541080B1 (ko) * | 2016-10-12 | 2023-06-08 | 리서치 트라이앵글 인스티튜트 | 복소환식 아펠린 수용체(apj) 작용제 및 이의 용도 |
WO2018100536A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
WO2019008487A1 (en) | 2017-07-05 | 2019-01-10 | Novartis Ag | NEW PHARMACEUTICAL COMPOSITION |
UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
PT3725791T (pt) * | 2017-12-13 | 2023-04-04 | Harbin Zhenbao Pharmaceutical Co Ltd | Sal que serve como inibidor de akt e seu cristal |
US20210300939A1 (en) | 2018-07-23 | 2021-09-30 | Signalrx Pharmaceuticals, Inc. | Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof |
JP2022512706A (ja) | 2018-10-16 | 2022-02-07 | エフ.ホフマン-ラ ロシュ アーゲー | 眼科におけるAkt阻害剤の使用 |
EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
TWI824069B (zh) | 2018-11-30 | 2023-12-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 用於hiv治療之化合物 |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
CN110031626A (zh) * | 2019-04-02 | 2019-07-19 | 浙江理工大学 | 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用 |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
AU2020327022A1 (en) | 2019-08-08 | 2022-02-10 | Laekna Limited | Method of treating cancer |
US20230147129A1 (en) | 2020-03-27 | 2023-05-11 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of synucleinopathies |
CN111620860B (zh) * | 2020-06-23 | 2023-02-03 | 济南健丰化工有限公司 | 一种福瑞塞替的制备方法 |
CN111592531B (zh) * | 2020-06-23 | 2023-08-15 | 上海鲲博玖瑞医药科技发展有限公司 | 福瑞塞替的制备方法 |
TW202222790A (zh) | 2020-10-01 | 2022-06-16 | 德商拜耳廠股份有限公司 | 製備4-溴呋喃-2-羧酸酯之方法 |
WO2023174210A1 (en) | 2022-03-14 | 2023-09-21 | Laekna Limited | Combination treatment for cancer |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023230541A1 (en) | 2022-05-27 | 2023-11-30 | Viiv Healthcare Company | Piperazine derivatives useful in hiv therapy |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1030415A (zh) | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | 饱和的杂环碳酰胺衍生物和它的制备方法 |
ES2005163A6 (es) | 1987-04-14 | 1989-03-01 | Lilly S A E | Un procedimiento para la produccion de derivados de tiofen-2-carboxamida. |
ES2075849T3 (es) | 1988-03-16 | 1995-10-16 | Smithkline Beecham Farma | Derivados heterociclicos. |
DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
DE3927483A1 (de) | 1989-08-19 | 1991-02-21 | Boehringer Ingelheim Kg | Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung |
US5258357A (en) | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
DE3933573A1 (de) | 1989-10-07 | 1991-04-18 | Basf Ag | Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
AU674553B2 (en) | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE69325662T2 (de) | 1992-10-23 | 2000-02-10 | Merck Sharp & Dohme | Dopamin rezeptor subtyp liganden |
FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
DE69418045T2 (de) * | 1993-08-06 | 1999-10-07 | Smithkline Beecham Plc | Amidderivate als 5ht1d rezeptor antagonisten |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
US5668148A (en) | 1995-04-20 | 1997-09-16 | Merck & Co., Inc. | Alpha1a adrenergic receptor antagonists |
JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
KR100423590B1 (ko) | 1995-08-02 | 2004-09-10 | 호따. 우리아치에씨아. 에세. 아. | 항진균활성을갖는신규피리미돈유도체 |
BR9606546A (pt) | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
CA2230082C (en) | 1995-08-22 | 2005-07-05 | Japan Tobacco Inc. | Amide compounds and use thereof |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5942544A (en) | 1996-02-22 | 1999-08-24 | Dupont Pharmaceuticals Company | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors |
EP0904076A1 (en) | 1996-04-03 | 1999-03-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036901A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036886A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250231A1 (en) | 1996-04-03 | 1997-10-09 | Robert P. Gomez | Inhibitors of farnesyl-protein transferase |
CA2249605A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2249665A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250936A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000509371A (ja) | 1996-04-03 | 2000-07-25 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
AU706314B2 (en) | 1996-04-03 | 1999-06-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AUPO163896A0 (en) | 1996-08-14 | 1996-09-05 | Resmed Limited | Determination of respiratory airflow |
AU6320998A (en) | 1997-02-21 | 1998-09-09 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
US5998336A (en) | 1997-02-26 | 1999-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same |
WO1998054164A1 (en) | 1997-05-30 | 1998-12-03 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
BR9815170A (pt) | 1997-12-12 | 2000-10-10 | Euro Celtique S A Luxembourg | "método de obter composto aplicável no tratamento de asma em mamìferos" |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AUPP433398A0 (en) | 1998-06-25 | 1998-07-16 | Australian National University, The | Compounds and processes |
US6192967B1 (en) | 1998-10-19 | 2001-02-27 | Sunny En Liung Huang | Collapsible auto shade |
US6130333A (en) | 1998-11-27 | 2000-10-10 | Monsanto Company | Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use |
GB9827882D0 (en) | 1998-12-17 | 1999-02-10 | Smithkline Beecham Plc | Novel compounds |
DE19904396A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Substituierte Pyrazolbenzylamin-Derivate |
DE19904397A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von Pyrazol-Carbonsäureamiden |
JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
HUP0203338A2 (hu) | 1999-04-13 | 2003-03-28 | Abbott Gmbh & Co. Kg | Integrin receptor ligandumok |
US6638980B1 (en) | 1999-05-24 | 2003-10-28 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
AU5155500A (en) | 1999-05-24 | 2000-12-12 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
EP1235807A1 (en) | 1999-11-24 | 2002-09-04 | Millennium Pharmaceuticals, Inc. | B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
CZ20013424A3 (cs) | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
CN1362953A (zh) * | 2000-02-05 | 2002-08-07 | 沃泰克斯药物股份有限公司 | 用作erk抑制剂的吡唑组合物 |
WO2001056993A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
ATE311366T1 (de) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | Benzamide und ähnliche inhibitoren vom faktor xa |
GB0011098D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands |
AU6469401A (en) | 2000-05-19 | 2001-11-26 | Serono Reproductive Biology In | Pharmaceutically active compounds and methods of use |
US6589195B1 (en) * | 2000-05-26 | 2003-07-08 | Orthomerica Products, Inc. | Modular adjustable prophylactic hip orthosis and adduction/abduction joint |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU2001277143A1 (en) | 2000-07-24 | 2002-02-05 | Davide Riccardo Grassetti | Inhibition of mutagenic effects of carcinogens |
GB0018758D0 (en) | 2000-07-31 | 2000-09-20 | Smithkline Beecham Plc | Novel use and compunds |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
ATE341539T1 (de) | 2001-01-26 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren |
EP1390353A1 (en) * | 2001-04-27 | 2004-02-25 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
DE10223912A1 (de) * | 2001-06-28 | 2003-01-16 | Merck Patent Gmbh | TN- und STN-Flüssigkristallanzeigen |
US20030015823A1 (en) * | 2001-07-18 | 2003-01-23 | Hydranautics | Method for forming a thick section, thermoset, solid casting |
EP1423380B1 (en) | 2001-08-03 | 2010-12-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
US6750239B2 (en) | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
EP1419161A1 (en) | 2001-08-24 | 2004-05-19 | PHARMACIA & UPJOHN COMPANY | Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease |
IL161047A0 (en) | 2001-09-27 | 2004-08-31 | Applied Research Systems | Pyrazole derivatives for increasing endogenous testosterone levels |
US6794252B2 (en) * | 2001-09-28 | 2004-09-21 | Texas Instruments Incorporated | Method and system for forming dual work function gate electrodes in a semiconductor device |
WO2003035619A1 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
WO2003039529A1 (en) | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
PL372198A1 (en) | 2002-02-06 | 2005-07-11 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
US7335779B2 (en) | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
GB0206861D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Medicaments |
JP2005527586A (ja) | 2002-04-05 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | 置換アリールアミド |
JP2005529889A (ja) | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | ピリミジン−2,4,6−トリオンメタロ−プロテイナーゼ阻害剤 |
WO2003104778A1 (en) | 2002-06-05 | 2003-12-18 | Pharmacia & Upjohn Company | Methods for identifying ligands using competitive binding 1h nmr experiments |
GB0216224D0 (en) | 2002-07-12 | 2002-08-21 | Glaxo Group Ltd | Compounds |
CA2494114A1 (en) | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
MXPA05001592A (es) | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
AU2003265395A1 (en) | 2002-08-14 | 2004-03-03 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
US6649638B1 (en) | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
JP2006501243A (ja) | 2002-08-23 | 2006-01-12 | カイロン コーポレイション | グリコーゲンシンターゼキナーゼ3のピロールベースのインヒビター |
DE10239443A1 (de) | 2002-08-28 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Blockiervorrichtung für ein Sperrspannwerk mit federbetätigtem Abtrieb |
EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
EP1581527A4 (en) | 2002-12-13 | 2006-11-22 | Smithkline Beecham Corp | MIMETICS OF THROMBOPOIETINE |
JP2006514043A (ja) | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物 |
JP2006517211A (ja) | 2003-02-10 | 2006-07-20 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Pgi2アンタゴニストとして使用するためのビス(ヘテロ)アリールカルボキサミド誘導体 |
US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
US7517887B2 (en) | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
TW200512195A (en) | 2003-04-21 | 2005-04-01 | Elan Pharm Inc | Benzamide 2-hydroxy-3-diaminoalkanes |
EP1628957B1 (en) | 2003-05-26 | 2010-09-29 | Takeda Pharmaceutical Company Limited | Sulfopyrroles |
MXPA05013645A (es) | 2003-06-20 | 2006-02-24 | Galderma Res & Dev | Nuevos compuestos moduladores de los receptores de tipo ppar gama y su utilizacion en composiciones cosmeticas o farmaceuticas. |
DE10331305A1 (de) | 2003-07-10 | 2005-02-17 | Siemens Ag | Kommunikationssystem, Peer-to-Peer-Nachrichten-Filter-Rechner und Verfahren zum Verarbeiten einer Peer-to-Peer-Nachricht |
FR2857666B1 (fr) | 2003-07-15 | 2005-08-26 | Oreal | Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane |
BRPI0412257A (pt) | 2003-07-23 | 2006-10-03 | Synta Pharmaceuticals Corp | compostos para inflamação e usos imuno-relacionados |
WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
CA2536470A1 (en) | 2003-08-15 | 2005-02-24 | Vertex Pharmaceuticals Incorporated | Pyrrole compositions useful as inhibitors of c-met |
WO2005019182A1 (en) | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists |
JP2007507547A (ja) | 2003-10-06 | 2007-03-29 | グラクソ グループ リミテッド | キナーゼ阻害剤としての1,7−二置換アザベンゾイミダゾールの調製 |
EP1670466A4 (en) | 2003-10-06 | 2007-04-25 | Glaxo Group Ltd | PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS |
EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
EP1684694A2 (en) | 2003-11-21 | 2006-08-02 | Array Biopharma, Inc. | Akt protein kinase inhibitors |
EP1706159B1 (en) | 2004-01-19 | 2013-06-26 | Atul Kumar | A system for distending body tissue cavities by continuous flow irrigation |
JP2007519753A (ja) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
US7521473B2 (en) | 2004-02-25 | 2009-04-21 | Wyeth | Inhibitors of protein tyrosine phosphatase 1B |
EP1730911A1 (en) * | 2004-03-30 | 2006-12-13 | Matsushita Electric Industries Co., Ltd. | Content relay server, content relay system, content relay method, and program using the same |
RU2006138036A (ru) * | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
JP2005336172A (ja) | 2004-04-26 | 2005-12-08 | Japan Tobacco Inc | 腎虚血再灌流障害治療又は予防薬 |
TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
US20080119456A1 (en) | 2004-05-29 | 2008-05-22 | Trond Ulven | Substituted Thiazoleacetic Acid as Crth2 Ligands |
JP2008503490A (ja) | 2004-06-17 | 2008-02-07 | センジェント・セラピューティクス・インコーポレイテッド | チロシンホスファターゼの三置換窒素調節物質 |
EP2325184A1 (en) * | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
US20060019968A1 (en) * | 2004-07-24 | 2006-01-26 | Laboratorios Dr. Esteve S.A. | Use of compounds active on the sigma receptor for the treatment of neuropathic pain |
US7269099B2 (en) | 2004-07-30 | 2007-09-11 | Bolt Technology Corporation | Air gun |
JP2006066488A (ja) * | 2004-08-25 | 2006-03-09 | Mitsubishi Electric Corp | 半導体受光素子およびその製造方法 |
US7365385B2 (en) * | 2004-08-30 | 2008-04-29 | Micron Technology, Inc. | DRAM layout with vertical FETs and method of formation |
US20060043513A1 (en) * | 2004-09-02 | 2006-03-02 | Deok-Hoon Kim | Method of making camera module in wafer level |
TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
US20060062453A1 (en) * | 2004-09-23 | 2006-03-23 | Sharp Laboratories Of America, Inc. | Color highlighting document image processing |
WO2006043518A1 (ja) | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
JP2006120339A (ja) | 2004-10-19 | 2006-05-11 | Matsushita Electric Ind Co Ltd | 高周波加熱電源装置 |
TW200619843A (en) | 2004-10-20 | 2006-06-16 | Sumitomo Bakelite Co | Semiconductor wafer and semiconductor device |
DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
BRPI0518296A2 (pt) | 2004-11-23 | 2008-11-11 | Wyeth Corp | antagonistas do receptor do hormânio liberador de gonadotropina |
EP1819709B1 (en) | 2004-11-30 | 2009-02-11 | Neurosearch A/S | Novel diazabicyclic aryl derivatives as cholinergy ligands |
SE527990C2 (sv) | 2004-12-06 | 2006-08-01 | Mora Of Sweden Ab | Isborr |
JP2008528700A (ja) | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pparモジュレーターとしての化合物および組成物 |
JP2006232707A (ja) | 2005-02-23 | 2006-09-07 | Japan Tobacco Inc | 癌転移抑制剤 |
CA2604442A1 (en) | 2005-04-11 | 2006-10-19 | Mingjun Huang | Pharmaceutical compositions for and methods of inhibiting hcv replication |
WO2006116355A1 (en) | 2005-04-22 | 2006-11-02 | Kalypsys, Inc. | Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
WO2006136829A2 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
US20060288588A1 (en) | 2005-06-22 | 2006-12-28 | Frank Morabito | Garden tool |
EP1933832A2 (en) * | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
WO2006136637A2 (es) * | 2005-06-24 | 2006-12-28 | Eloy Antonio Martinez Albal | Implante dental de corona rotatoria |
BRPI0612124A2 (pt) | 2005-06-24 | 2010-10-19 | Genelabs Tech Inc | derivados de heteroarila para o tratamento de viroses |
AU2006261845C1 (en) | 2005-06-27 | 2013-05-16 | Exelixis Patent Company Llc | Imidazole based LXR modulators |
CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
GB0518237D0 (en) | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
EP1968568A4 (en) * | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
PL1962830T3 (pl) | 2005-12-23 | 2013-08-30 | Glaxosmithkline Llc | Azaindolowe inhibitory kinaz aurora |
AR056882A1 (es) | 2006-02-01 | 2007-10-31 | Bayer Cropscience Sa | Derivados del fungicida n- cicloalquil- bencil- amida |
EP2465850B1 (en) | 2006-02-28 | 2016-11-23 | Dart Neuroscience (Cayman) Ltd | Therapeutic compounds |
JP2007277230A (ja) | 2006-03-15 | 2007-10-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
EP2125739A1 (en) | 2006-12-22 | 2009-12-02 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
ES2543325T3 (es) | 2007-02-07 | 2015-08-18 | Glaxosmithkline Llc | Inhibidores de la actividad de Akt |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
WO2008121685A1 (en) | 2007-03-28 | 2008-10-09 | Smithkline Beecham Corporation | Methods of use for inhibitors of akt activity |
EP2134175A4 (en) | 2007-03-29 | 2012-01-11 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
-
2008
- 2008-02-01 UY UY30892A patent/UY30892A1/es not_active Application Discontinuation
- 2008-02-04 CL CL200800348A patent/CL2008000348A1/es unknown
- 2008-02-05 TW TW097104414A patent/TWI381836B/zh active
- 2008-02-05 TW TW100116246A patent/TWI507194B/zh active
- 2008-02-05 JO JOP/2008/0045A patent/JO3134B1/ar active
- 2008-02-05 PE PE2008000249A patent/PE20090058A1/es not_active Application Discontinuation
- 2008-02-05 AR ARP080100487A patent/AR066184A1/es active IP Right Grant
- 2008-02-07 KR KR1020127026684A patent/KR101521002B1/ko active IP Right Grant
- 2008-02-07 EP EP08729249.6A patent/EP2117523B1/en active Active
- 2008-02-07 JP JP2009549232A patent/JP4723677B2/ja active Active
- 2008-02-07 EA EA200970738A patent/EA018038B1/ru not_active IP Right Cessation
- 2008-02-07 US US12/526,111 patent/US8410158B2/en active Active
- 2008-02-07 SI SI200831277T patent/SI2117523T1/sl unknown
- 2008-02-07 MX MX2013002178A patent/MX367398B/es unknown
- 2008-02-07 PL PL08729249T patent/PL2117523T3/pl unknown
- 2008-02-07 UA UAA200908388A patent/UA102992C2/ru unknown
- 2008-02-07 KR KR1020097018537A patent/KR101537825B1/ko active IP Right Grant
- 2008-02-07 NZ NZ579177A patent/NZ579177A/en not_active IP Right Cessation
- 2008-02-07 MY MYPI20093241A patent/MY164480A/en unknown
- 2008-02-07 CA CA2678255A patent/CA2678255C/en active Active
- 2008-02-07 WO PCT/US2008/053269 patent/WO2008098104A1/en active Application Filing
- 2008-02-07 KR KR1020147027676A patent/KR20140140570A/ko not_active Application Discontinuation
- 2008-02-07 CN CN2008800106329A patent/CN101646427B/zh active Active
- 2008-02-07 ES ES08729249.6T patent/ES2501518T3/es active Active
- 2008-02-07 PT PT87292496T patent/PT2117523E/pt unknown
- 2008-02-07 SG SG2012025235A patent/SG193678A1/en unknown
- 2008-02-07 DK DK08729249.6T patent/DK2117523T3/da active
- 2008-02-07 AU AU2008213694A patent/AU2008213694B2/en active Active
- 2008-02-07 US US12/027,454 patent/US8273782B2/en active Active
- 2008-02-07 MX MX2009008550A patent/MX2009008550A/es active IP Right Grant
- 2008-02-07 BR BRPI0807146A patent/BRPI0807146B8/pt active IP Right Grant
- 2008-12-23 US US12/342,620 patent/US20110071182A1/en not_active Abandoned
-
2009
- 2009-07-31 ZA ZA200905363A patent/ZA200905363B/xx unknown
- 2009-08-03 IL IL200212A patent/IL200212A/en active IP Right Grant
- 2009-08-05 DO DO2009000196A patent/DOP2009000196A/es unknown
- 2009-08-06 MA MA32146A patent/MA31167B1/fr unknown
- 2009-08-06 CO CO09082387A patent/CO6220930A2/es active IP Right Grant
- 2009-08-26 CR CR10995A patent/CR10995A/es unknown
- 2009-10-01 US US12/571,828 patent/US20100041726A1/en not_active Abandoned
-
2010
- 2010-01-08 HK HK10100158.6A patent/HK1132676A1/xx unknown
-
2011
- 2011-02-07 JP JP2011024171A patent/JP5010038B2/ja active Active
-
2012
- 2012-04-10 JP JP2012089471A patent/JP5511879B2/ja active Active
-
2013
- 2013-02-22 US US13/774,022 patent/US8946278B2/en active Active
-
2014
- 2014-08-20 HR HRP20140790AT patent/HRP20140790T1/hr unknown
- 2014-09-08 CY CY20141100723T patent/CY1115535T1/el unknown
- 2014-12-08 US US14/562,968 patent/US20150152092A1/en not_active Abandoned
-
2016
- 2016-04-13 US US15/097,608 patent/US20160287561A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970738A1 (ru) | Ингибиторы активности akt | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
CY1117546T1 (el) | Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου | |
TW200801008A (en) | Protein kinase inhibitors | |
BRPI0510177A (pt) | heterociclos monocìclicos como inibidores de cinase | |
NO20082476L (no) | Bicykliske forbindelser med kinaseinhiberende aktivitet | |
EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
EA201270553A1 (ru) | Ингибиторы тирозинкиназы брутона | |
TW200604184A (en) | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | |
ATE532789T1 (de) | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
PC4A | Registration of transfer of a eurasian patent by assignment | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KZ KG |